
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The FDA has approved tadalafil (Cialis), a new oral PDE-5 inhibitor, for the treatment of erectile dysfunction.





